| Aug 15 |
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 14 |
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 14 |
Arcutis Biotherapeutics GAAP EPS of -$0.42 beats by $0.09, revenue of $30.85M beats by $1.77M
|
| Aug 14 |
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 13 |
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long
|
| Aug 7 |
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
|
| Aug 1 |
Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
|
| Jul 30 |
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
|
| Jul 29 |
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
|
| Jul 29 |
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
|
